01.06.21
Ingredient supplier Deerland Probiotics and Enzymes recently announced the publication of a clinical trial which provides evidence that supplementation with a probiotic strain, Bacillus Subtilis DE111, has a beneficial effect on symptoms experienced by preschool-aged children with GI infections.
The study, published in the Journal of Probiotics and Health, is an IRB-approved, double-blind, randomized, placebo-controlled trial involving 81 children between the ages of 2 and 6 who attended daycare. It is a follow-up study to a similarly designed clinical trial which found that the administration of DE111 modified the microbiome composition of preschool-aged children in a way which promoted alpha-diversity, causing six Bacteroidetes believed to support inflammatory and immune responses to flourish.
Daycare-attending children were a demographic of particular interest to researchers due to the fact that they experience an elevated likelihood of contracting respiratory and gastrointestinal infections compared to most, which is especially true during winter months.
In the present study, DE111 was evidenced to reduce the duration of vomiting and hard stools, and improved overall gastrointestinal discomfort, the authors said. Vomiting duration was reduced to two days on average, versus 14 days in the placebo group throughout the duration of the experiment. Children in the probiotic group had 0 days of hard stools on average compared to the placebo group, which experienced this symptom for 15 days. Lastly, children in the probiotic group had 18 days of reported GI discomfort, compared to 48 days in the placebo group.
Only 7.1% of the probiotic group had incidences of gastrointestinal infection compared to 20.5% in the placebo group. Those in the probiotic group who did contract a GI infection had it for 8 days, compared to 28 days in the placebo group.
The researchers concluded that treatment with this probiotic supported a healthy gastrointestinal tract, with a reduced duration of vomiting, hard stools, and overall gastrointestinal discomfort, and that the trial demonstrated this probiotic is safe for use in children between the ages of 2 and 6.
“This is highly encouraging research showing that supplementation with the probiotic DE111 can help support the health of young children in preschool, via the gastrointestinal system,” John Deaton, vice president of science and technology at Deerland Probiotics, said.
The study, published in the Journal of Probiotics and Health, is an IRB-approved, double-blind, randomized, placebo-controlled trial involving 81 children between the ages of 2 and 6 who attended daycare. It is a follow-up study to a similarly designed clinical trial which found that the administration of DE111 modified the microbiome composition of preschool-aged children in a way which promoted alpha-diversity, causing six Bacteroidetes believed to support inflammatory and immune responses to flourish.
Daycare-attending children were a demographic of particular interest to researchers due to the fact that they experience an elevated likelihood of contracting respiratory and gastrointestinal infections compared to most, which is especially true during winter months.
In the present study, DE111 was evidenced to reduce the duration of vomiting and hard stools, and improved overall gastrointestinal discomfort, the authors said. Vomiting duration was reduced to two days on average, versus 14 days in the placebo group throughout the duration of the experiment. Children in the probiotic group had 0 days of hard stools on average compared to the placebo group, which experienced this symptom for 15 days. Lastly, children in the probiotic group had 18 days of reported GI discomfort, compared to 48 days in the placebo group.
Only 7.1% of the probiotic group had incidences of gastrointestinal infection compared to 20.5% in the placebo group. Those in the probiotic group who did contract a GI infection had it for 8 days, compared to 28 days in the placebo group.
The researchers concluded that treatment with this probiotic supported a healthy gastrointestinal tract, with a reduced duration of vomiting, hard stools, and overall gastrointestinal discomfort, and that the trial demonstrated this probiotic is safe for use in children between the ages of 2 and 6.
“This is highly encouraging research showing that supplementation with the probiotic DE111 can help support the health of young children in preschool, via the gastrointestinal system,” John Deaton, vice president of science and technology at Deerland Probiotics, said.
